Enliven Therapeutics Inc
NASDAQ:ELVN
Relative Value
There is not enough data to reliably calculate the relative value of ELVN.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
ELVN Competitors Multiples
Enliven Therapeutics Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Enliven Therapeutics Inc
NASDAQ:ELVN
|
1.1B USD | 0 | -15.3 | -10.1 | -10.1 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
715B USD | 19.9 | 116.3 | 57.1 | 65 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 16.5 | 45.2 | 33.7 | 37 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
363B USD | 4.2 | 9.4 | 11.6 | 15.2 | ||
US |
Merck & Co Inc
NYSE:MRK
|
325.9B USD | 5.3 | 141.1 | 35.2 | 57.5 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
190.7B GBP | 5 | 37.7 | 174.5 | 278.4 | ||
CH |
Novartis AG
SIX:NOVN
|
181.8B CHF | 3.4 | 11.4 | 8.7 | 12.7 | ||
CH |
Roche Holding AG
SIX:ROG
|
181.9B CHF | 3.1 | 15.8 | 9 | 10.7 | ||
US |
Pfizer Inc
NYSE:PFE
|
161.2B USD | 2.9 | -522.7 | 12.9 | 20.5 |